A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults
That is the name of it, Phase 1/2/3. They don’t state on that page how many participants.
Phase 1 is often just 30 people.